Mirum Pharmaceuticals (NASDAQ: MIRM) net income
Mirum Pharmaceuticals reported a net loss of $23.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $87.9m. Earnings per share were −$0.47.
Fiscal 2025 is the highest of the 7 fiscal years on record for Mirum Pharmaceuticals. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$23.4m | — | −4.5% | −$0.47 |
| 2024 | −$87.9m | — | −26.1% | −$1.85 |
| 2023 | −$163.4m | — | −87.7% | −$4.00 |
| 2022 | −$135.7m | — | −176.0% | −$4.01 |
| 2021 | −$84.0m | — | −438.9% | −$2.77 |
| 2020 | −$103.3m | — | — | — |
| 2019 | −$52.6m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Mirum Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Mirum Pharmaceuticals ranks 215th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Mirum Pharmaceuticals, −4.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 213th | Stereotaxis | −$21.6m | −66.8% |
| 214th | Inogen | −$22.7m | −6.5% |
| 215th | Mirum Pharmaceuticals | −$23.4m | −4.5% |
| 216th | Castle Biosciences | −$24.2m | −7.0% |
| 217th | ClearPoint Neuro | −$25.5m | −69.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Mirum Pharmaceuticals
- How much did Mirum Pharmaceuticals earn in fiscal 2025?
- Mirum Pharmaceuticals reported a net loss of $23.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $87.9m.
- What are the earnings per share of Mirum Pharmaceuticals?
- They were −$0.47 in fiscal 2025, compared with −$1.85 in fiscal 2024.
- Where does Mirum Pharmaceuticals rank in its sector by net income?
- It ranks 215th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Mirum Pharmaceuticals come from?
- From the annual report (Form 10-K) that Mirum Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Mirum Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Mirum Pharmaceuticals: the Mirum Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.